Clinical Trials · NCT03492580
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Janssen Research & Development, LLC
- Enrollment
- 714,582
- Start date
- Feb 2018
- Locations
- 1 site, United States
- Primary endpoint
- Number of Hospitalizations for Heart Failure